[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100539177":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":27,"centralContacts":32,"locations":40,"responsibleParty":68,"collaborators":70,"id":74,"slug":18,"hasResults":75,"nctId":76,"briefTitle":77,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":75,"sex":80,"minAge":81,"maxAge":18,"enrollmentInfo":82,"targetDuration":18,"studyType":85,"phases":86,"briefSummary":88,"conditions":89,"keywords":93,"overallStatus":42,"whyStopped":18,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},{"fullName":5,"class":6},"Brigham and Women's Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Alert","EXPERIMENTAL","Alert-based CDS will consist of an on-screen electronic alert that will notify the clinician that the patient has an indication for LDL-C-lowering therapy but is not prescribed any. The clinician will have the opportunity to proceed to an order template through which appropriate lipid-lowering can be prescribed. The clinician could also elect to learn more about current evidence-based recommendations for LDL-C lowering in the PAD population. Finally, the clinician could elect to proceed without ordering oral LDL-C-lowering therapy or reading evidence-based recommendations for LDL-C lowering but would have to provide a rationale for not doing so.",[13],"Behavioral: Computer Alert",{"label":15,"type":16,"description":17,"interventionNames":18},"No Alert","NO_INTERVENTION","No on-screen notification will be issued to the clinician",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"BEHAVIORAL","Computer Alert","On-screen alert-based decision support raising awareness of need for lipid-lowering therapy in patients with peripheral artery disease",[9],[26],"EPIC Best Practice Advisory",[28],{"name":29,"affiliation":30,"role":31},"Gregory Piazza","BWH","PRINCIPAL_INVESTIGATOR",[33,37],{"name":29,"role":34,"phone":35,"phoneExt":18,"email":36},"CONTACT","6177326984","gpiazza@bwh.harvard.edu",{"name":38,"role":34,"phone":35,"phoneExt":18,"email":39},"Candrika D Kharaini","cdkhairani@@bwh.harvard.edu",[41],{"facility":5,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"RECRUITING","Boston","Massachusetts","02115","United States","US",{"type":49,"coordinates":50},"Point",[51,52],-71.05977,42.35843,{"lat":52,"lon":51},[55,58,60,61,64,66],{"name":56,"role":34,"phone":57,"phoneExt":18,"email":36},"Gregory Piazza, MD, MS","617-732-6984",{"name":18,"role":34,"phone":18,"phoneExt":59,"email":36},"Piazza",{"name":56,"role":31,"phone":18,"phoneExt":18,"email":18},{"name":62,"role":63,"phone":18,"phoneExt":18,"email":18},"Samuel Goldhaber, MD","SUB_INVESTIGATOR",{"name":65,"role":63,"phone":18,"phoneExt":18,"email":18},"Ron Blankstein, MD",{"name":67,"role":63,"phone":18,"phoneExt":18,"email":18},"Jorge Plutzky, MD",{"type":31,"investigatorFullName":56,"investigatorTitle":69,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Associate Director, Thrombosis Research Group",[71],{"name":72,"class":73},"Esperion Therapeutics, Inc.","INDUSTRY","100539177",false,"NCT06300450","Randomized Controlled Trial of Alert-Based Computerized Decision Support for Patients With Peripheral Artery Disease Not Prescribed Lipid-Lowering Therapy","PAD-ALERT","Inclusion Criteria:\n\n* All patients ≥ 18 years old\n* Seen in Cardiovascular Medicine Clinic, Primary Care, Podiatry, Vascular Surgery, and Diabetology\n* Medical history entry, visit diagnosis, or problem list entry of PAD\n* Not prescribed LDL-C-lowering therapy\n\nExclusion Criteria:\n\n* Patients taking a statin, ezetimibe, bempedoic acid, a PCSK9 inhibitor, inclisiran or a combination will be excluded","ALL","18 Years",{"count":83,"type":84},400,"ESTIMATED","INTERVENTIONAL",[87],"NA","This single-center, 400-patient, randomized controlled trial assesses the impact of a patient- and provider-facing EPIC Best Practice Advisory (BPA; alert-based computerized decision support tool) to increase guideline-directed utilization of statin and statin-alternative oral LDL-C lowering therapies in patients with PAD who are not being prescribed LDL-C-lowering therapy.",[90,91,92],"Peripheral Artery Disease","Peripheral Vascular Diseases","Dyslipidemias",[94,90,95,96],"Dyslipidemia","Peripheral Vascular Disease","Computerized Decision Support","2026-06-16",{"date":99,"type":100},"2026-06-17","ACTUAL",{"date":102,"type":100},"2023-03-01",{"date":104,"type":84},"2026-12-30",{"name":5,"class":6},1]